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Abstract
Background  and  objectives:  Serious  functional  and  structural  alterations  of  gastrointestinal
tract are  observed  in  failure  of  blood  supply,  leading  to  gastrointestinal  dismotility.  Activation
of opioid  receptors  provides  cardioprotective  effect  against  ischemia--reperfusion  (I/R)  injury.
The aim  of  the  present  study  was  to  determine  whether  or  not  remifentanil  could  reduce  I/R
injury of  small  intestine.
Methods:  Male  Wistar  Albino  rats  were  subjected  to  mesenteric  ischemia  (30  min)  followed  by
reperfusion  (3  h).  Four  groups  were  designed:  sham  control;  remifentanil  alone;  I/R  control;  and
remifentanil  +  I/R.  Animals  in  remifentanil  +  I/R  group  were  subjected  to  infusion  of  remifentanil
(2 ug  kg−1 min−1)  for  60  min,  half  of  which  started  before  inducing  ischemia.  Collecting  the
ileum tissues,  evaluation  of  damage  was  based  on  contractile  responses  to  carbachol,  levels  of
lipid peroxidation  and  neutrophil  inﬁltration,  and  observation  of  histopathological  features  in
intestinal tissue.
Results:  Following  reperfusion,  a  signiﬁcant  decrease  in  carbachol-induced  contractile
response,  a  remarkable  increase  in  both  lipid  peroxidation  and  neutrophil  inﬁltration,  and  a  sig-
niﬁcant injury  in  mucosa  were  observed.  An  average  contractile  response  of  remifentanil  +  I/R
group was  signiﬁcantly  different  from  that  of  the  I/R  group.  Lipid  peroxidation  and  neutrophil
inﬁltration were  also  signiﬁcantly  suppressed  by  the  treatment.  The  tissue  samples  of  the  I/R
group were  grade  4  in  histopathological  evaluation.  In  remifentanil  +  I/R  group,  on  the  other
hand, the  mucosal  damage  was  moderate,  staging  as  grade  1.
Conclusions:  The  pretreatment  with  remifentanil  can  attenuate  the  intestinal  I/R  injury  at  a by  lowering  lipid  peroxidation  and  leukocyte  inﬁltration.
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Pré-tratamento  com  remifentanil  protege  contra  a  reduc¸ão da  contratilidade
intestinal  relacionada  à  lesão  de  isquemia  e  reperfusão  em  ratos
Resumo
Justiﬁcativa  e  objetivos:  Alterac¸ões  funcionais  e  estruturais  sérias  do  trato  gastrointestinal  são
observadas na  insuﬁciência  de  irrigac¸ão  sanguínea,  levando  a  alterac¸ões  da  motilidade  gastroin-
testinal. A  ativac¸ão  dos  receptores  opioides  proporciona  um  efeito  cardioprotetor  contra  a  lesão
de isquemia/reperfusão  (I/R).  O  objetivo  do  presente  estudo  foi  determinar  se  remifentanil
pode ou  não  reduzir  a  lesão  de  I/R  do  intestino  delgado.
Métodos:  Ratos  machos  albinos,  da  linhagem  Wistar,  foram  submetidos  à  isquemia  mesentérica
(30 minutos)  seguida  de  reperfusão  (3  horas).  Quatro  grupos  foram  designados:  sham  controle;
remifentanil  isolado;  controle  I/R;  remifentanil  +  I/R.  Os  animais  do  grupo  remifentanil  +  I/R
foram submetidos  à  infusão  de  remifentanil  (2  g  kg−1 min−1)  por  60  min,  metade  dos  quais
iniciou antes  da  induc¸ão  da  isquemia.  Coletando  os  tecidos  do  íleo,  a  avaliac¸ão  dos  danos  foi
baseada nas  respostas  contráteis  ao  carbacol,  nos  níveis  de  peroxidac¸ão  lipídica  e  inﬁltrac¸ão
de neutróﬁlos  e  na  observac¸ão  das  características  histopatológicas  no  tecido  intestinal.
Resultados:  Após  a  reperfusão,  uma  diminuic¸ão  signiﬁcativa  da  resposta  contrátil  induzida  por
carbacol,  um  notável  aumento  tanto  da  peroxidac¸ão  lipídica  quanto  da  inﬁltrac¸ão  de  neutróﬁlos
e uma  lesão  signiﬁcativa  da  mucosa  foram  observados.  A  média  da  resposta  contrátil  no  grupo
remifentanil  +  I/R  foi  signiﬁcativamente  diferente  daquela  do  grupo  I/R.  A  peroxidac¸ão  lipídica
e a  inﬁltrac¸ão  de  neutróﬁlos  também  foram  signiﬁcativamente  suprimidas  pelo  tratamento.  As
amostras de  tecido  do  grupo  I/R  apresentaram  grau  4  na  avaliac¸ão  histopatológica.  No  grupo
remifentanil  +  I/R,  por  outro  lado,  a  lesão  da  mucosa  foi  moderada,  apresentando  estadiamento
de grau  1.
Conclusões:  O  pré-tratamento  com  remifentanil  pode  atenuar  a  lesão  intestinal  de  I/R  em  um
grau notável,  possivelmente  pela  reduc¸ão  da  peroxidac¸ão  lipídica  e  da  inﬁltrac¸ão  leucocitária.
© 2013  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os
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ntroduction
ctivated  opioid  receptors  (ORs)  protects  against
schemia/reperfusion  (I/R)  injury  in  heart  and  neurons.1--3
pioid  peptides  and  ORs  are  present  in  gut.4,5 An  ultra-
hort-acting  phenylpiperidine  opioid  analgesic,  remifentanil
s  cardioprotective  against  the  I/R  injury  via  mediating
Rs,1,6 activating  protein  kinase  C  (PKC),  and  driving
itochondrial  ATP-sensitive  potassium  (KATP)  channels7
hich  mimic  ischemic  preconditioning  (PC).1,8
Sepsis,  hemorrhage,  intestinal  transplantation,  severe
urns,  and  mesenteric  thrombosis  cause  mesenteric
schemia,9,10 making  a  dramatic  impact  on  the  intes-
ine.  Intestinal  I/R  have  a  major  role  in  the  development
f  primary  graft  dysfunction.11,12 The  intestinal  tissue
s  very  sensitive  to  the  I/R.  In  fact,  even  though  the
astrointestinal  tract  represents  about  5%  of  the  body
eight,  its  oxygen  consumption  constitutes  roughly  20%
f  the  total  oxygen  usage.13 Interruption  of  the  oxygen
upply  decreases  the  intracellular  ATP  content,  dis-
urbing  the  cellular  homeostasis  through  the  increased
eactive  oxygen  species  (ROS).  Reperfusion  induces  struc-
ural  and  functional  damage  of  mucosa  and  interstitial
dema  (reperfusion  injury),14 which  is  primarily  due  to
he  generation  of  ROS  from  various  sources  including
he  electron  transport  chains  of  mitochondria,  xanthine
xidase  metabolism,  prostaglandins,  endothelial  cells,
nd  activated  neutrophils.14--17 I/R  damages  the  mucosal
arrier  function,  causing  the  mucosal  and  vascular  per-
eabilities  and  bacterial  translocation,  ending  up  with
A
A
wystemic  inﬂammation  and  multiple-organ  failure.18 It  also
hanges  the  contractile  response  of  the  intestinal  smooth
uscle,19--22 which  is  associated  with  the  local  inﬂamma-
ory  response  augmented  by  the  inﬁltrating  neutrophils10
nd  ROS.23
Some  pharmacological  agents  including  anesthetics  pro-
uce  PC.24--28 Speciﬁcally,  ORs  are  involved  in  the  PC  of  rat
eart.7,8 Moreover,  pharmacologic  postconditioning  induced
y  remifentanil  also  protects  against  the  I/R-induced  cardiac
njury.3 On  the  other  hand,  whether  or  not  the  possible  ben-
ﬁcial  effect  occurs  in  the  intestinal  I/R  injury  is  extremely
imited.  Only  one  study  by  Cho  et  al.29 reports  that
emifentanil  protects  the  intestine  against  I/R  injury.  They
learly  demonstrate  that  remifentanil  signiﬁcantly  reduces
xidative  stress,  inﬂammatory  response,  and  tissue  injury.
owever,  they  did  not  study  directly  the  effect  on  physiologi-
al  functions  of  the  tissue  (e.g.  contractility).  Therefore,  our
im  was  to  determine  whether  remifentanil  has  beneﬁcial
ffect  on  the  I/R-disturbed  intestinal  contractility.  We  eval-
ated  the  contractile  response,  histopathological  changes
nd  measured  the  tissue  levels  of  malondialdehyde  (MDA),
ipid  peroxidation  marker,  and  myeloperoxidase,  neutrophil
nﬁltration  marker,  (MPO).
aterials and methodsnimals
 total  of  32  Wistar  adult  male  rats  weighing  220  ±  20  g
ere  used  in  the  study.  The  animals  were  obtained  from  the
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hRemifentanil  protects  intestinal  motility  
Bulent  Ecevit  University  Animal  Care  Unit  and  housed  under
standard  conditions.  They  had  free  access  to  commercial
chow  and  water.  On  the  day  before  the  surgical  procedures,
the  animals  were  fasted  overnight  but  allowed  ad  libitum
access  to  water.  They  were  maintained  in  their  cages  at
a  constant  room  temperature  using  a  12  h:12  h  light/dark
cycle.  All  of  the  procedures  described  here  were  approved
by  the  local  animal  ethics  committee  of  the  institution.
Operative  procedures
Rats  were  anesthetized  with  sodium  thiopental  intraperi-
toneally  (60  mg  kg−1)  followed  by  conducting  laparotomy
through  a  midline  incision  into  the  peritoneal  cavity.  After
the  small  bowel  was  exteriorized  gently  to  the  left  onto
moist  gauze,  animals  were  subjected  to  30  min  of  ischemia
by  ligation  of  the  superior  mesenteric  artery  (SMA),  using
3/0  silk  thread.  Intestinal  ischemia  was  conﬁrmed  by  the
lack  of  pulse  in  the  mesenteric  artery  and  the  pale  color
of  the  jejunum  and  ileum.  Afterward,  the  intestines  were
returned  to  the  abdomen,  which  was  closed  with  2  small
clamps.  At  the  end  of  30  min  of  ischemia,  the  abdomen  was
reopened  and  the  thread  was  gently  removed  to  allow  reper-
fusion  of  the  blood  ﬂow,  which  was  conﬁrmed  by  observing
the  pulsation  of  the  artery  and  its  branches  on  the  intes-
tine.  Body  temperature  was  maintained  at  37.8 ◦C  by  heating
lamp  during  the  procedure  of  I/R.
Experimental  groups
Animals  were  divided  into  4  groups  each  of  8  animals:  (a)
Sham  control  group,  animals  underwent  laparotomy  without
performing  the  occlusion  of  SMA;  (b)  Sham  plus  remifentanil
(remifentanil  alone)  group,  rats  were  treated  with  remifen-
tanil  and  a  sham  operation  without  SMA  occlusion;  (c)  I/R
control  group,  the  SMA  was  occluded  for  30  min  followed
by  3  h  of  reperfusion;  (d)  I/R  plus  remifentanil  group,  rats
subjected  to  I/R  were  treated  with  remifentanil.
Remifentanil  (Glaxo  Group  Limited,  Lake  Forest,  IL,  USA)
pretreatment  was  carried  out  by  infusion  (2  g  kg−1 min−1)
via  tail  vein  for  30  min  prior  to  the  occlusion  of  SMA  and
for  additional  30  min  during  the  whole  period  of  ischemia.
Catheterization  of  the  tail  vein  was  carried  out  with  a 24-
g  Polyneo  catheter  (Polymed,  Poly  Medicure  Ltd.,  Haryana,
India)  for  administration  of  the  infusion.  Animals  in  the  sham
control  and  the  I/R  groups  were  instead  given  sterile  serum
physiological  solution  in  the  same  volume.  Following  the
reperfusion  period,  the  animals  were  killed  by  administra-
tion  of  anesthetic  at  lethal  doses;  thereafter,  samples  of
ileum  were  collected  and  processed  for  each  experimental
protocol.
lleal  longitudinal  muscle  contractility
The  ileal  longitudinal  muscle  contractile  activity  was  eval-
uated  in  isolated  ileal  segments  after  3  h  of  reperfusion  in
an  organ  bath.  Strips  of  longitudinal  muscle  at  5-mm  length
were  removed  1  cm  away  from  the  ileocecal  junction.  After
removing  the  ﬁrst  strip  for  histological  evaluation,  second,
third,  and  fourth  samples  at  the  same  size  were  collected
d
w
0
w485
or  contractility  and  biochemical  analyses.  Strips  were  lon-
itudinally  suspended  under  2-g  load  in  20  mL  organ  bath
lled  with  Krebs  solution  (in  mmol  L−1: NaCl,  118.5;  KCl,
.8;  KH2PO4,  1.2;  MgSO4·7H2O,  1.2;  CaCl2 1.9;  NaHCO3,  25;
lucose,  10.1).  The  solution  was  gassed  with  a  mixture  of
%  CO2 and  95%  O2 and  maintained  at  37 ◦C.  After  60  min
quilibration  with  2  g  load,  carbachol  was  added  to  the
rgan  bath  at  ﬁnal  various  concentrations  ranging  from  10−7
o  10−2 mol  L−1. Active  force  development  was  recorded  at
ach  concentration  to  determine  the  dose-response  rela-
ionship.  Isometric  force  was  monitored  by  external  force
isplacement  transducer  (FDA-10A,  Commat  Co,  Ankara,
urkey)  using  MP  30  software  (MP30  Biopac  Systems  Inc,
anta  Barbara,  CA,  USA).
istopathologic  scoring  of  the
schemia--reperfusion  injury  to  small  intestine
he  segments  of  ileum  were  ﬁxed  in  10%  formalin  and
mbedded  in  parafﬁn.  Intestinal  parafﬁn  sections  were
tained  with  hematoxylin  and  eosin  for  morphological
nalysis.  Histopathological  evaluation  of  the  reperfused-
ntestinal  tissue  was  based  on  a  staging  method  described  by
ierholzer  et  al.30 and  the  evaluation  was  graded  from  0  to
.  In  grade  0,  no  speciﬁc  pathological  changes  are  observed:
ormal  structure  of  gut  wall,  including  villi,  crypts,  lamina
ropria,  and  muscularis  externa.  In  grade  1,  mild  mucosal
amage  is  assessed:  denudation  of  villi  epithelium,  other-
ise  normal  structure.  In  grade  2,  moderate  damage  occurs:
oss  of  villus  length  and  epithelial  sloughing  with  evidence  of
ongestion,  hemorrhage,  and  inﬂammation  in  the  mucosa,
ut  no  change  in  submucosa  or  muscularis  externa.  In  grade
,  extensive  damage  is  observed:  loss  of  a  large  number
f  villi  including  denudation,  sloughing,  and  the  presence
f  granulomatous  tissue  with  the  damage  localized  to  sub-
ucosa  and  muscularis.  In  grade  4,  there  is  severe  damage
nd  necrosis:  inﬂammation  and  necrosis  in  areas  through-
ut  the  thickness  of  the  intestinal  wall.  The  investigator
ho  performed  these  measurements  was  unaware  of  the
xperimental  design.
etermination  of  tissue  MDA  activity
ntestinal  lipid  peroxide  levels  were  measured  by  a  method
escribed  by  Casini  et  al.31 Brieﬂy,  by  using  a  motor-driven
estle,  tissue  samples  were  homogenized  in  ice-cold  TCA
y  adding  10  mL  of  10%  TCA  per  gram  of  tissue.  Following
entrifugation,  750  L  of  supernatant  was  added  to  equal
olume  of  0.67%  thiobarbituric  acid  and  heated  to  100 ◦C  for
5  min.  The  absorbance  of  the  samples  was  then  measured
pectrophotometrically  at  535  nm.
etermination  of  tissue  MPO  activity
he  activity  of  MPO  within  the  supernatant  of  the
omogenate  was  determined  from  the  H2O2-dependent  oxi-
ation  of  o-dianisidine.32 Aliquots  of  supernatant  (0.1  mL)
ere  added  to  2.9  mL  of  reaction  mixture  containing
.167  mg  mL−1 of  o-dianisidine,  and  20  mM  of  H2O2 solution,
hich  were  prepared  in  50  mM  of  PB.  Immediately  after
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dding  the  aliquot  to  the  mixture,  the  change  in  absorbance
t  460  nm  was  measured  for  5  min.  One  unit  of  MPO  activity
as  deﬁned  as  that  degrading  1  mol  of  peroxide  per  min
t  25 ◦C.  The  activity  was  then  normalized  as  unit  per  mg  of
issue  (U  mg−1).
ata  analysis
alues  for  the  experiments  dealing  with  contractility  were
ormalized  for  per  g  of  tissue.  Each  data  point  represents
ean  ±  S.E.M.  For  statistical  evaluation,  SPSS  11.0  statisti-
al  software  package  program  was  used  (SPSS  Inc.,  Chicago,
L,  USA).  Non-parametric  tests  were  performed  since  each
roup  consisted  of  eight  replicate  samples.  Thus,  using
ruskal--Wallis  variance  analysis  (ANOVA),  all  groups  were
ompared  in  terms  of  existence  of  heterogeneity.  Once  sta-
istically  meaningful  heterogeneity  was  detected  among  all
roups,  individual  groups  were  compared  with  each  other
y  employing  Tukey’s  test.  p  Values  of  less  than  0.05  were
onsidered  signiﬁcant.
esults
leal  longitudinal  muscle  contractility
arbachol  caused  a  dose-dependent  contractile  effect  on
he  terminal  ileum  segments  from  all  groups,  providing  sig-
oid  curves  with  their  maximal  responses  (Emax values)
Fig.  1).  The  Emax value  for  carbachol  was  signiﬁcantly  lower
n  the  I/R  control  than  in  the  sham  group  (12.83  ±  0.76  vs.
2.19  ±  2.10  g/g  tissue,  respectively).  In  other  words,  the
ontraction  in  response  to  carbachol  was  signiﬁcantly  and
ose-dependently  reduced  by  the  induction  of  I/R,  as  indi-
ated  by  a  downward  shift  of  the  curve.  The  statistical
ifference  between  these  groups  was  signiﬁcant  at  all  doses
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igure  1  Concentration--response  curves  of  carbachol  in
ongitudinal  ileum  muscle  isolated  from  the  sham  control,
ham  +  Rem,  IR  control,  and  IR  +  Rem.  Each  data  point  is  the
ean ±  S.E.M.  of  eight  experiments.  *p  <  0.05  indicates  statisti-
ally meaningful  difference  from  the  IR  control  group  (IR  control
s all  other  three  groups  at  each  concentration  of  carbachol).
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f  carbachol  (p  <  0.01).  Reduced  contractility  was  signiﬁ-
antly  ameliorated  by  the  treatment  of  remifentanil.  This
ffect  was  statistically  signiﬁcant  at  each  dose  of  carbachol,
ompared  to  the  I/R  group.  As  seen  in  Fig.  1,  contrac-
ion  responses  of  sham  group,  remifentanil  alone  group,
nd  remifentanil  +  I/R  group,  however,  provided  a  similar
urves  at  all  carbachol  doses,  being  statistically  indifferent
rom  each  other  (p  >  0.05).  Comparing  Emax values,  the  I/R
roup  (12.83  ±  0.76  g/g  tissue)  was  only  about  58%  of  the
ham  group  (22.19  ±  2.10  g/g  tissue).  Average  Emax value  of
he  sham  group  was  not  statistically  different  from  those
f  the  both  remifentanil  alone  (21.55  ±  2.85  g/g  tissue)  and
emifentanil  +  I/R  (24.60  ±  2.86  g/g  tissue)  groups.
istopathological  ﬁndings
nalyzing  six  sections  per  group,  the  most  dramatic  alter-
tions  were  observed  in  the  I/R  group  (Fig.  2C;  Table  1).
nﬂammation,  mucosal  denudation,  and  edema  were  clearly
etected  on  some  parts  of  the  mucosa  and  submucosa  in
ddition  to  necrotic  areas  throughout  the  intestinal  wall.
loughing  on  some  of  the  surface  epithelium  was  also  obvi-
us.  The  I/R  group  was,  therefore,  evaluated  as  grade  4.
n  the  sham  group,  as  demonstrated  in  Fig.  2A,  normal
tructure  of  gut  wall  with  villi,  crypts,  lamina  propria,  and
uscularis  layer  was  clearly  observed.  The  group  was  given  a
rade  0.  Remifentanil  alone  group  has  provided  very  similar
ppearances  to  those  observed  in  the  sham  group;  namely,
o  speciﬁc  pathological  changes  were  observed;  thus,  it  was
raded  as  0  (Fig.  2B).  Remifentanil  +  I/R  group  has  moder-
te  mucosal  damage  with  only  minimal  focal  denudations  of
he  villi  epithelium;  therefore,  the  group  received  a  grade
 (Fig.  2D).
DA  levels
he  MDA  content  of  the  sham  group  animals  averaged
3.29  ±  7.46  nmol  g−1 tissue,  while  animals  subjected  only
o  the  I/R  were  found  to  have  156.82  ±  15.74  nmol  g−1 tissue
Fig.  3),  a  signiﬁcant  increase  in  MDA  content  (p  <  0.001).
retreatment  with  remifentanil  (remifentanil  +  I/R  group)
igniﬁcantly  reduced  the  I/R-induced  intestinal  MDA  content
o  the  sham  group  levels.  With  an  average  value  of
07.80  ±  8.93  nmol  g−1 tissue,  this  group  was  statistically
ndistinguishable  from  the  sham  group  (p  = 0.143),  but  statis-
ically  different  from  the  I/R  group  (p  =  0.02).  On  the  other
and,  the  average  MDA  content  in  the  remifentanil  alone
Table  1  Semi-quantitative  histological  grading  of  cross-
sections  of  the  rat  ileum  (6  sections/group).
Mean  ±  S.E.M.
Sham  control  0
Sham +  Remifentanil  0
I/R control  3.83  ±  0.16
I/R +  Remifentanil 1.17  ±  0.16a
Analyzing with one-way ANOVA, statistical signiﬁcance among
two groups.
a p = 0.00005.
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Figure  2  Light  micrographs  of  the  rat  intestinal  tissue:  (A)  Sham-operated  control  group;  normal  architecture  of  intestinal  wall
with no  any  pathological  alteration  (grade  0);  (B)  Sham  +  Rem;  normal  histomorphologic  appearance  of  intestinal  tissue  (grade  0);
(C) I/R  control;  the  most  extensive  morphological  alterations  detected,  such  as  ulcered  intestinal  lumen,  signiﬁcantly  decreased
muscular layer,  loss  of  epithelium  and  glands,  and  having  superﬁcial  exuda  and  mucoid  material  (grade  4);  (D)  IR  +  Rem;  the  pretreat-
ment improves  histopathological  alterations  observed  after  the  I/R;  inﬂammated  intestinal  tissue  with  moderate  mucosal  thinning,
ion  w
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completely  abolished  the  increased  enzymatic  activitypatchy loss  of  epithelium,  and  mix  type  inﬂammatory  cell  react
(H&E stain  ×  200,  Scale  bar  =  50  m).  (Rem;  remifentanil,  I/R;  i
group  (84.03  ±  14.90  nmol  g−1 tissue)  was  not  statistically
different  from  that  in  the  sham  group  (p  =  0.946).
MPO  activityThe  average  MPO  enzyme  activities  of  the  tissues  from  ani-
mals  subjected  to  sham  operation,  remifentanil  alone,  I/R,
and  remifentanil  +  I/R  were  (in  U  mg−1 tissue)  0.63  ±  0.17,
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Figure  3  Average  malondialdehyde  (MDA)  content  of  ileum
samples  from  the  sham  control,  sham  +  Rem  control,  IR  con-
trol,  and  IR  +  Rem.  Data  are  expressed  as  mean  ±  S.E.M.  (n  =  8).
Compared  to  the  IR  control  group,  statistically  signiﬁcant
difference  is  denoted  as  *(p  <  0.05).  (Rem;  remifentanil,  IR;
ischemia--reperfusion).
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.54  ±  0.08,  1.60  ±  0.28,  and  0.83  ±  0.14,  respectively
Fig.  4).
The  I/R  caused  approximately  a  2.5-fold  increase  in  the
PO  activity  of  the  tissue  compared  to  the  basal  level  of
he  activity  (p  =  0.004).  Pretreatment  with  remifentanilesulting  from  the  I/R  insult;  the  MPO  activity  of  samples
rom  animals  pretreated  with  remifentanil  was  signiﬁcantly
ifferent  from  that  in  the  I/R  group  (p  =  0.049).  No  statis-
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igure  4  Average  myeloperoxidase  (MPO)  activity  of  the
leum samples  collected  from  the  sham  control,  sham  +  Rem
ontrol,  I/R  control,  and  IR  +  Rem.  Data  are  presented  as
ean ±  S.E.M.  of  eight  animals  in  each  group.  Compared  to  the
R control  group,  statistically  signiﬁcant  difference  is  denoted
s *(p  <  0.05).
4t
t
D
T
s
E
i
c
a
e
f
w
a
m
d
r
r
d
i
s
H
o
s
s
w
d
i
m
i
a
a
r
l
h
w
i
s
n
a
r
w
c
t
t
m
e
c
r
o
m
i
a
t
c
m
r
m
w
o
c
r
t
o
s
a
t
s
a
o
l
a
t
t
i
i
i
h
c
t
t
o
a
m
M
w
t
s
i
b
c
i
i
p
p
P
i
g
P
w
i
l
p
T
c
n
n
s
a
b
ﬁ
t
o
p88  
ical  difference  was  observed  in  the  MPO  activity  between
he  sham-group  and  the  remifentanil  alone  group.
iscussion
he  present  study  demonstrates  that  remifentanil  may  have
trong  protective  potential  against  the  intestinal  I/R  injury.
vidences  indicate  that  remifentanil  attenuates  the  I/R-
nduced:  (1)  intestinal  pathological  changes;  (2)  decrease  in
ontractile  response;  (3)  increased  neutrophil  inﬁltration;
nd  (4)  elevated  lipid  peroxidation.
There  are  many  published  studies  that  show  beneﬁcial
ffects  of  pharmacological  PC  with  remifentanil  on  reper-
usion  injury  of  various  tissues.  However,  those  concerned
ith  pharmacological  PC  of  the  intestine  with  remifentanil
re  very  limited  and  lacking  functional  aspects,  such  as
otility  and  secretion.  In  fact,  only  one  study  has  been
ealing  with  this  question.  Cho  et  al.29 have  shown  that
emifentanil  attenuates  intestinal  I/R  injury  in  mice  by
educing  lipid  peroxidation  and  systemic  inﬂammation.  Our
ata  conﬁrmed  the  outcomes  of  this  study  in  regard  to  the
nhibition  of  oxidative  stress  and  inﬂammation  and  demon-
trated  the  direct  involvement  of  leukocytes  in  tissues.
owever,  the  study  did  not  directly  investigate  the  effect
f  remifentanil  on  physiological  functions  of  the  tissue,
uch  as  motility  and/or  secretion.  Therefore,  the  current
tudy  takes  a  further  step,  showing  that  the  pretreatment
ith  remifentanil  ameliorates  the  reduced  contractility
ue  to  I/R----a  novel  ﬁnding  potentially  linked  to  the  anti-
nﬂammatory  and  antioxidant  activity  of  remifentanil.
Intestinal  I/R  may  cause  multiple  organ  failure,  severe
orbidity,  and  even  death.1,16 Both  acute  and  chronic
schemia  make  a  substantial  impact  on  gut  functionally
s  well  as  structurally,  leading  to  dismotility,  abnormal
bsorption,  and  altered  barrier  function  against  bacte-
ial  translocation.10,14,33 Acute  intestinal  I/R  causes  such
ong-term  structural  alterations  as  the  development  of
ypertrophy,  cellular  dysfunction,  neuronal  death,  necrosis
ithin  the  myenteric  plexus,19,22,33 and  the  inﬁltration  of
nﬂammatory  cells  (i.e.,  neutrophils).30,34 Many  published
tudies  demonstrate  deleterious  effects  of  I/R  on  intesti-
al  motility,  such  as  delayed  gastrointestinal  transit,35--37
ltered  migrating  motor  complex,38 and  impaired  motor
esponse  to  any  stimulation.20,39,40 Inﬂammatory  response
ithin  the  muscular  cells  and  decrease  in  contractility  of  the
ircular  smooth  muscle  are  triggered  by  I/R.30,34 Integrity  of
he  enteric  neuronal  network  is  necessary  for  normal  gas-
rointestinal  motility.  Therefore,  the  I/R  may  disturb  the
otor  function  of  the  gut  by  altering  the  properties  of
nteric  neurons  or  the  neuro-effector  transmission.22 These
hanges  are  probably  the  outcome  of  the  inﬂammatory
esponse  induced  by  the  I/R  injury.  The  intestinal  damage  we
bserved  may  be  associated  with  the  inﬂammation,  which  is
arked  speciﬁcally  with  an  increased  amount  of  neutrophils
n  the  tissue.  Inhibiting  the  activation  and  the  endothelial
dherence  of  neutrophils  reduce  the  I/R-induced  damage  to
he  mucosa.41 In  response  to  the  inﬂammation  of  the  mus-
le,  neutrophils  are  activated,  contributing  possibly  to  the
uscle  damage.  Therefore,  the  motility  disturbance  occur-
ing  after  the  I/R  was  more  likely  resulted  from  the  severe
uscle  damage  and  associated  inﬂammatory  reaction  that
O
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e  observed.  The  treatment  with  remifentanil  reduced  not
nly  the  lipid  peroxidation  in  the  tissue  but  also  the  leuko-
yte  inﬁltration,  tissue  damage,  and  disturbed  contractile
esponse.
Returning  of  the  oxygenated  blood  to  the  ischemic  intes-
ine  further  exacerbates  the  tissue  damage  mainly  because
f  the  increased  generation  of  ROS,  causing  oxidative
tress.17,42 Primary  sources  of  ROS  during  the  reperfusion
re  xanthine  oxidase  and  activated  neutrophils  releasing
he  pro-inﬂammatory  mediators  and  cytotoxic  substances,
uch  as  MPO.17 Intestinal  reperfusion  injury  is  regarded  as
n  inﬂammatory  disease  characterized  with  the  recruitment
f  leukocytes.9 ROS  liberated  in  reperfusion  further  stimu-
ate  inﬂammatory  response,  enhancing  the  recruitment  and
ctivation  of  neutrophils.  The  tissue  MPO  activity,  propor-
ional  to  the  amount  of  accumulated-neutrophils,  mirrors
he  mucosal  injury  and  the  rate  of  neutrophil  inﬁltration
n  postischemic  tissue.17,43 Hence,  following  the  I/R,  the
ncreased  MPO  activity  in  the  tissue  indicated  the  enhanced-
nﬂammatory  response  in  the  current  study.  The  elevated
istologic  scoring  of  the  tissue  lesions  and  the  decreased
ontractile  response  coincided  with  the  signiﬁcant  eleva-
ion  of  both  MPO  activity  and  lipid  peroxidation  of  the
issue  in  I/R  group.  One  of  the  deleterious  consequences
f  oxidative  damage  is  lipid  peroxidation,  which  eventu-
lly  causes  structural  and  functional  disturbances  to  the
embranes.  Signiﬁcant  reduction  in  both  MPO  activity  and
DA  content  were  observed  in  the  remifentanil  +  I/R  group
hich  indicates  a  signiﬁcant  limitation  to  the  inﬂamma-
ion.  Moreover,  contractile  response  to  carbachol  in  the
ame  group  appeared  to  be  maintained  very  close  to  that
n  the  sham  control  group.  These  ﬁndings  were  supported
y  the  histopathological  observation  that  remifentanil  suc-
essfully  rescued  the  integrity  of  the  tissue  from  I/R
njury.
The  opioid-induced  PC  protects  against  the  cardiac  I/R
njury.  Speciﬁcally,  PC  by  remifentanil,  an  ultra-short-acting
henylpiperidine  opioid  analgesic,  conﬁrms  the  cardio-
rotection.3 Activation  of  -  and  -ORs  was  involved  in
KC  activation,  opening  of  mitochondrial  KATP  channel,  and
ncreasing  anti-apoptotic  protein  expression,  important  tar-
ets  of  cardio-protection  in  ischemic  and  pharmacologic
C.7,8 The  toll-like  receptor  signaling  in  inﬂammatory  path-
ay  is  also  associated  with  the  opioid-induced  protection
n  brain  and  cell  cultures.  Following  activation  of  the  toll-
ike  receptor  2,  opioid  agonists  have  an  inhibitory  effect  on
roinﬂammatory  cytokine  production  in  human  monocytes.
he  inhibition  is  mediated  exclusively  by  -ORs.2 In  the
urrent  study,  we  recognized  that  the  integrity  of  intesti-
al  mucosa  and  contractile  response  of  the  tissue  remained
early  normal  in  remifentanil  +  I/R  group.  Our  data  demon-
trated  that  remifentanil  decreased  both  lipid  peroxidation
nd  neutrophil  accumulation  in  ischemic  tissue  which  may
e  accounted  for  underlying  mechanism  of  above  mentioned
ndings.  However,  it’d  have  been  better  and  conﬁrmative
o  evaluate  the  effects  of  an  antagonist/agonist  of  -ORs
n  the  present  model  besides  examining  a  dose-response
attern  of  remifentanil.Cells  in  the  gastrointestinal  tract  form  a site  in  which  the
Rs  exist  at  high  levels.  The  presence  of  ORs  along  the  tract
s  demonstrated  in  nerve  and  smooth  muscle.4 Many  studies
eport  that  the  protection  by  remifentanil  is  mediated  by
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ORs.44--46 On  the  other  hand,  some  suggest  the  mediation  of
OR-independent  mechanism.2 However,  Zhang  et  al.5 show
that  the  endogenous  opioid  peptides  might  play  a  major  role
in  ischemic  PC  of  the  small  intestine.  In  model  of  croton
oil-induced  inﬂammation  of  mice  intestine,  expression  of
the  -OR  is  reported  to  be  up-regulated  in  the  myenteric
plexus  of  jejunum.  Similarly,  patients  with  IBD  have  an
increased  expression  of  -OR  mRNA  in  their  inﬂamed  small
bowel  and  colon  in  respect  to  the  healthy  intestinal  tissue.47
In  the  present  study,  we  do  not  know  whether  the  protective
effect  of  remifentanil  is  mediated  through  OR-dependent
mechanisms  or  not.  However,  it  is  tempting  to  speculate  that
the  beneﬁcial  effect  is  due  to  the  OR-mediated  processes
since  the  tissue  has  an  abundant  amount  of  ORs  and  since  the
inﬂammatory  insults  induce  the  up-regulation  of  the  ORs.
If  this  is  the  case,  then  the  pretreatment  with  remifen-
tanil  possibly  mimics  the  effect  of  ischemic  PC.  Namely,
acting  via  ORs,  remifentanil  may  eventually  activate  PKC
through  the  turnover  of  phosphatidylinositol  induced  by  the
activation  of  the  membrane-bound  phospholipase  C  or  D.
PKC  then  phosphorylates  and  stabilizes  the  open  state  of
both  the  mitochondrial  and  the  sarcolemmal  KATP  chan-
nels  which  ultimately  elicits  cytoprotection  as  observed  in
remifentanil-induced  cardioprotection.7 The  pretreatment
with  remifentanil  may  also  have  an  OR-mediated  inhibitory
effect  on  the  generation  of  proinﬂammatory  cytokines  by
monocytes  in  response  to  the  stimulation  of  toll-like  recep-
tor  2.2 In  these  cases,  the  administration  of  an  OR  antagonist
(i.e.  Naloxone)  would  have  been  detrimental  to  the  pre-
ventive  effects  observed  in  the  present  study.  On  the  other
hand,  if  the  mechanisms  are  non-receptor-mediated,  the
remifentanil-induced  intestinal  protection  may  be  multifac-
torial.  In  this  case,  as  reported  on  remifentanil  PC  of  hepatic
I/R,  inducible  nitric  oxide  synthase  (iNOS)  may  mediate  the
preventive  effects  in  intestinal  tissue.  For  instance,  both
lipid  peroxidation  and  inﬂammation  could  be  attenuated
by  an  elevated  generation  of  the  endogenous  nitric  oxide
(NO)  which  would  limit  the  amount  of  ROS  and  attenuate
the  inﬂammatory  response.  It  is  well  documented  that  the
endogenous  NO  may  exhaust  ROS  and  neutrophil-mediated
tissue  injury;  hence,  reducing  inﬂammatory  response  signif-
icantly.  It  is  also  shown  that  the  cellular  damage  induced  by
the  I/R  is  involved  with  a  signiﬁcant  decrease  of  NO.  There-
fore,  remifentanil  may  be  associated  with  the  induction  of
iNOS  expression  and  consequent  generation  of  the  endoge-
nous  NO  in  intestinal  tissue  challenging  to  the  reperfusion
injury.  If  so,  the  protective  effects  would  have  been  blocked
by  a  NOS  inhibitor  but  not  with  Naloxone.2
In  conclusion,  we  have  demonstrated  that  the  treatment
of  rats  with  remifentanil  prior  to  the  I/R  provided  protection
against  I/R-induced  mucosal  damage  and  contractile  dis-
turbance.  Possible  mechanism  responsible  for  these  salutary
activities  of  remifentanil  may  probably  be  multifactorial.
However,  as  the  present  study  has  given  evidences,  the
attenuation  of  neutrophil  inﬁltration  and  the  reduction  of
oxidative  stress  appear  to  be  of  primary  importance  to  get
the  beneﬁcial  effects.  Further  studies,  which  will  focus  on
the  mechanisms  of  protective  effects  of  remifentanil  in
depth,  are  required  for  sure.  In  conclusion,  we  have  shown
that  the  administration  of  remifentanil  during  ischemia
could  efﬁciently  be  protective  against  the  most  histologi-
cal,  cytological,  biochemical,  and  physiological  aspects  of
1489
ntestinal  injury,  providing  therapeutic  potential  for  clini-
al  application  in  intestinal  ischemia  and  ischemia-related
isorders.  Moreover,  the  current  study  implicates  that  the
pplication  of  remifentanil  as  analgesic  agent  may  be
referred  for  those  suffering  from  intestinal  hypoperfusion
nd  undergoing  anesthesia.
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